<DOC>
	<DOCNO>NCT02120404</DOCNO>
	<brief_summary>The purpose study : - evaluate hemodynamic tolerance esmolol titrate obtain lowering heart rate 10 % 20 % .</brief_summary>
	<brief_title>Pilot Phase II Study : Hemodynamic Tolerance Anti-inflammatory Effects Esmolol During Treatment Septic Shock</brief_title>
	<detailed_description>During septic shock , consequence treatment β1-blocker inflammation cardiovascular variability unknown . The use esmolol positive effect inflammation hemodynamic tolerance . These effect probably dose-dependent . The study enroll adult patient hospitalize ICU , severe septic shock require treatment vasopressor . A total 45 patient include . Among 45 patient , 15 patient randomize control group . 30 patient randomize Esmolol objective decrease heart rate 10 % ( Group G10 , n=15 ) 20 % ( Group G20 , n=15 ) . Esmolol administer 24 hour . This multicenter study perform 3 investigation site . The following parameter evaluate different moment 28 day follow patient , mainly : - Origin sepsis , SOFA score . - Hemodynamic parameter continuously record 24 hour experimental period . - Cardiovascular variability ( arterial pressure heart rate ) record 24 hour . - 3 echocardiogram H0 , H12 H24 perform . - Biological parameter sample H0 , H6 , H12 H24 : They include standard biological parameter ( Urea , Creatinin , Bilirubin , …… ) specific parameter ( catecholamine , vasopressin , insulin , cortisol , proinflammatory cytokine anti-inflammatory cytokine . Dosages perform H0 , H12 H24 order study : - The expression adrenergic receptor genetic polymorphism circulate immune cell . - The Th1/Th2 balance immune cell . Each patient followed-up 28 day . The variation MAP cardiac output induce esmolol exceed 15 % baseline value . If variation important esmolol administration stop hemodynamical tolerance define poor .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Esmolol</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Adult age &gt; 18 year Hospitalization septic shock Patient arterial catheter , central venous catheter PVC PiCCO Consent sign patient . In absence consent sign patient , consent family member seek . As soon possible , patient inform ask sign consent continue study Hemodynamic stability patient 1 hour without change norepinephrine dosage Treatment noradrenaline le 24 hour Need noradrenaline &gt; 3 mg/h Treatment dobutamine Personal history severe asthma Personal history severe chronic obstructive pulmonary disease Personal history pulmonary hypertension Personal history second degree third degree atrioventricular block without pacemaker Personal history sinoatrial block without pacemaker Chronic heart failure ejection fraction &lt; 40 % Severe atrioventricular nodal bradycardia ( heart rate &lt; 70 bpm ) Mean arterial pressure &lt; 65 mm Hg Hypersensitivity esmolol Prinzmetal angina Pheochromocytoma without treatment Pregnancy woman Breastfeeding woman Peripheral arterial disease Patient pacemaker Chronic treatment beta blocker Concomitant treatment bepridil , diltiazem , verapamil , amiodarone , propafenone , Class Ia antiarrythmics ( hydroquinidine , disopyramide ) baclofen Patient &lt; 18 year patient care guardian Therapeutic futility Lack medical insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>septic shock , hemodynamic tolerance , esmolol</keyword>
</DOC>